Zimmer Biomet (NYSE:ZBH) Upgraded to “Hold” at Zacks Research

Zacks Research upgraded shares of Zimmer Biomet (NYSE:ZBH) from a strong sell rating to a hold rating in a report issued on Tuesday morning,Zacks.com reports.

Several other analysts have also weighed in on the stock. Stifel Nicolaus raised their price objective on shares of Zimmer Biomet from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wall Street Zen downgraded Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Wells Fargo & Company decreased their price target on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 29th. Citizens Jmp cut their price objective on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a research report on Wednesday, April 29th. Finally, Royal Bank Of Canada boosted their price objective on Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $104.42.

Zimmer Biomet Trading Up 1.2%

Shares of ZBH stock opened at $101.41 on Tuesday. The firm has a fifty day moving average of $93.40 and a 200-day moving average of $91.31. The stock has a market cap of $19.34 billion, a price-to-earnings ratio of 24.67, a P/E/G ratio of 2.72 and a beta of 0.45. Zimmer Biomet has a 52-week low of $79.12 and a 52-week high of $107.85. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.06. The firm had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The company’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, equities research analysts forecast that Zimmer Biomet will post 8.54 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider directly owned 27,251 shares in the company, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.28% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ZBH. Brighton Jones LLC acquired a new position in shares of Zimmer Biomet during the fourth quarter valued at $204,000. Sivia Capital Partners LLC acquired a new stake in Zimmer Biomet in the second quarter worth about $232,000. United Bank raised its holdings in Zimmer Biomet by 10.7% during the 2nd quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock worth $1,085,000 after purchasing an additional 1,153 shares during the last quarter. Federated Hermes Inc. lifted its position in Zimmer Biomet by 129.2% during the 2nd quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock valued at $194,000 after purchasing an additional 1,202 shares during the period. Finally, Cerity Partners LLC boosted its stake in shares of Zimmer Biomet by 93.6% in the 2nd quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock valued at $7,004,000 after purchasing an additional 37,116 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.